Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. The companies mission is to accelerate the discovery of new medicines from the laboratory into development to treat patients with a range of debilitating and fatal diseases.
Sygnature adds significant value to collaborations by providing advanced scientific knowledge and intellectual input to accelerate clients drug discovery projects through to pre-clinical candidate.
Sygnature undertakes target validation, hit identification, hit-to-lead and lead optimisation projects, and complete drug discovery programmes for pharmaceutical companies worldwide. Core capabilities include medicinal chemistry, in vitro bioscience, computational sciences and informatics, DMPK/physical sciences and protein crystallography. Sygnature has an enviable track record of success for delivering multiple drug candidates on client projects, currently there are 8 drug candidates in the clinic invented at Sygnature since 2011.
ADME/Toxicology/Pharmacokinetics, Analogue preparation, Chemistry services, Drug design, Hit to lead- discovery and optimisation